The World Finally Accepts a Much-Maligned Covid Shot
Bloomberg 2 hrs ago
Indonesia, one of the first nations to bet its Covid-19 vaccination campaign on Sinovac Biotech Ltd., was about to announce a stunning development, one that would help vindicate a shot that’s been shrouded in controversy for months. Over in Beijing, though, the company’s chief executive officer was unaware.
A study of some 128,000 Jakarta health workers released Wednesday found Sinovac’s vaccine known as CoronaVac was far more protective than clinical trials had indicated. A day earlier, it wasn’t mentioned by CEO Yin Weidong in a wide-ranging interview with Bloomberg reporters, and representatives later confirmed the company didn’t know the announcement was coming.
91 A healthcare worker prepares a dose of Sinovac s vaccine for the coronavirus disease during a mass vaccination for medical workers at the Istora Senayan stadium in Jakarta on Feb 4 this year. (Reuters photo)
Indonesia, one of the first nations to bet its Covid-19 vaccination campaign on Sinovac Biotech, was about to announce a stunning development, one that would help vindicate a shot that’s been shrouded in controversy for months. Over in Beijing, though, the company’s chief executive officer was unaware.
A study of some 128,000 Jakarta health workers released Wednesday found Sinovac’s vaccine known as CoronaVac was far more protective than clinical trials had indicated.
Chinese Shot Takes Controversial Path to Vaccinating the World
Bloomberg News, Bloomberg News Weidong Yin , Getty Images via Bloomberg
(Bloomberg) Indonesia, one of the first nations to bet its Covid-19 vaccination campaign on Sinovac Biotech Ltd., was about to announce a stunning development, one that would help vindicate a shot thatâs been shrouded in controversy for months. Over in Beijing, though, the companyâs chief executive officer was unaware.
A study of some 128,000 Jakarta health workers released Wednesday found Sinovacâs vaccine known as CoronaVac was far more protective than clinical trials had indicated. A day earlier, it wasnât mentioned by CEO Yin Weidong in a wide-ranging interview with Bloomberg reporters, and representatives later confirmed the company didnât know the announcement was coming.
May 3, 2021 Share
Russia is turning to multiple Chinese firms to manufacture the Sputnik V coronavirus vaccine in an effort to speed up production as demand soars for its shot.
Russia has announced three deals totaling 260 million doses with Chinese vaccine companies in recent weeks. It’s a decision that could mean quicker access to a shot for countries in Latin America, the Middle East, and Africa that have ordered Russia’s vaccine, as the U.S. and the European Union focus mainly on domestic vaccination needs.
Earlier criticism about Russia’s vaccine have been largely quieted by data published in the British medical journal The Lancet that said large-scale testing showed it to be safe, with an efficacy rate of 91%.
May 4, 2021
TAIPEI, Taiwan (AP) Russia is turning to multiple Chinese firms to manufacture the Sputnik V coronavirus vaccine in an effort to speed up production as demand soars for its shot.
Russia has announced three deals totaling 260 million doses with Chinese vaccine companies in recent weeks. It’s a decision that could mean quicker access to a shot for countries in Latin America, the Middle East, and Africa that have ordered Russia’s vaccine, as the U.S. and the European Union focus mainly on domestic vaccination needs.
Earlier criticism about Russia’s vaccine have been largely quieted by data published in the British medical journal The Lancet that said large-scale testing showed it to be safe, with an efficacy rate of 91%.